What Limits Residual Solvent Clearance in 85:15 DL-PLG Depot Microspheres?

In solvent-extraction microsphere manufacture, LACTEL 85:15 DL-PLG (B6006-1) is dissolved in dichloromethane at a polymer-to-solvent ratio between 1:4 and 1:10 w/v, selected against the lot intrinsic viscosity because dispersed-phase viscosity above 1500 mPa·s at 25 °C routinely shifts droplet coalescence and broadens particle size distribution. The drug is either co-dissolved with the polymer or suspended as micronized solid at a total drug load below 30% w/w. The organic phase is emulsified into an aqueous continuous phase containing 0.5–2.0% w/v poly(vinyl alcohol) of 87–89% hydrolysis degree. Continuous-phase temperature is held at 4–10 °C because water plasticization depresses the glass transition of high-lactide PLGA and can cause primary emulsion droplets to coalesce if local jacket temperature exceeds the wet-Tg. Rotor-stator dispersion at 5,000–20,000 rpm for 2–5 min produces a primary emulsion; on scale-up, the energy density of a laboratory rotor-stator does not transfer directly to a high-pressure homogenizer, and droplet size must be re-qualified against tip speed, gap setting, and residence time. Solvent extraction is carried out in a hardening vessel containing a 10–25-fold volume of chilled 1–2% v/v isopropanol or aqueous PVA at 4–10 °C under overhead agitation at 200–600 rpm. This cold extraction step controls dichloromethane clearance without collapsing the microspheres into fused agglomerates. Washing with water-for-injection is repeated 3–5 times to remove surface poly(vinyl alcohol), and the suspension is sieved to isolate the 25–125 µm or 45–75 µm fraction. Terminal lyophilization is performed with a cryoprotectant such as mannitol at 2–5% w/w of the wet microsphere mass. Residual dichloromethane is controlled to 600 µg/g under ICH Q3C(R8); USP 71 sterility, USP 85 bacterial endotoxin, USP 788 subvisible particulate, and ISO 10993-5 cytotoxicity are standard release and safety anchors. Sterilization is not performed by steam because the amorphous copolymer hydrolyzes at moist heat; aseptic processing or terminal gamma at 25–40 kGy may be used, and gamma irradiation lowers molecular weight and accelerates release, requiring dose mapping and stability correlation. The terminal product is a lyophilized vial for intramuscular or subcutaneous injection after reconstitution with water-for-injection or a suitable diluent.

Injection molding of amorphous 85:15 DL-PLG into small-fragment fixation devices demands a three-stage vacuum drying operation before melt processing. The resin is dried at 40 °C under vacuum until residual moisture is below 0.05% w/w; higher water levels at melt temperatures cause hydrolytic chain scission and viscosity loss that cannot be reversed. Production-scale micro-molding machines with 14–18 mm screws and compression ratios below 2.0:1 are favored because high shear heating degrades PLGA. Reported barrel profiles for high-lactide PLGA span 140–180 °C, with the feed throat at 80–100 °C and the nozzle held 5–10 °C below the metering zone to limit shear-induced chain scission. Residence time is maintained below 5 min, and nitrogen purge is applied to the hopper and feed throat. Mold temperature is set at 15–25 °C because the copolymer is amorphous and does not require crystallization; mold surfaces are mirror-polished to reduce ejection drag. Holding pressure between 600–900 bar and injection velocity below 50 mm/s are used to avoid gate streaking and short-shots, which are common failure modes when melt viscosity drops or freeze-off occurs too quickly. After ejection, parts are annealed at 35–45 °C under nitrogen for 4–8 h to relieve orientation without spherulitic aging. Intrinsic viscosity is checked by size exclusion chromatography after molding; a molecular weight loss above 20% of the virgin lot typically rejects the batch for critical load-bearing claims. The use window remains small-fragment fixation, such as interference screws, tacks, and suture anchors, because amorphous 85:15 PLGA lacks the tensile modulus of poly(L-lactide) and is not specified for cortical bone plates. Sterilization is performed with ethylene oxide under ISO 11135:2014, followed by degassing below residue limits; steam and dry heat are excluded because the glass transition begins near 42–55 °C and deformation occurs before sterilization hold temperatures are reached. Compliance testing references ASTM F2502-17 for bioabsorbable internal fixation, ISO 10993-6 for local effects after implantation, and ISO 10993-10 for delayed-type hypersensitivity.

When High-Lactide PLGA Coatings Are Sprayed onto Cobalt-Chromium Stents

Before high-lactide PLGA coatings are sprayed onto cobalt-chromium stents, the bare-metal substrate is cleaned, passivated, and often surface-primed to improve interfacial adhesion; otherwise, the amorphous 85:15 coating can delaminate during crimping or balloon expansion. The coating solution is formed by dissolving 85:15 DL-PLG (B6006-1) at 1–5% w/w in a 1:1 v/v acetone–tetrahydrofuran mixture; the drug is co-dissolved or suspended at a polymer-to-drug mass ratio between 2:1 and 4:1. An ultrasonic spray nozzle operating at 20–60 kHz delivers the solution at 0.05–0.2 mL/min while a drying gas at 60–80 °C removes solvent. The stent is rotated and translated under the nozzle to build a conformal coating of 5–15 µm thickness; thicker films are avoided because fracture toughness of plasticized PLGA is low and balloon expansion can open circumferential cracks. The high-lactide composition is selected for slower degradation and extended elution compared with 50:50 PLGA, but the amorphous film has a low glass transition; drug plasticization can pull the wet glass transition below 37 °C, producing tack and self-adhesion on automated stent loading lines. Residual tetrahydrofuran is controlled to 720 µg/g and acetone to 5000 µg/g under ICH Q3C(R8), with vacuum drying at 40 °C for 72 h under nitrogen. Coating integrity after crimping and nominal expansion is inspected by scanning electron microscopy and by light obscuration testing under USP 788; biological evaluation is anchored to ISO 10993-4:2017 for hemocompatibility, ISO 10993-5 for cytotoxicity, and ISO 10993-10 for irritation and sensitization. Ethylene oxide sterilization may be incompatible with some drug loads because the polymer absorbs moisture during conditioning, and gamma irradiation at typical terminal doses accelerates chain scission; process selection must be integrated with the drug stability profile. The terminal product is a drug-eluting stent on a cobalt-chromium platform, in which the 85:15 PLGA layer controls release of an antiproliferative agent without serving as a structural component.

Nonwoven tubular scaffolds electrospun from 85:15 DL-PLG use a spinning solution prepared at 10–20% w/w in either 3:1 v/v chloroform–methanol or hexafluoroisopropanol; the solvent is selected for volatility and conductivity, and the polymer concentration is adjusted to the lot intrinsic viscosity. The solution is delivered through a 22 G blunt needle at 0.8–2.5 mL/h while a positive potential of 15–25 kV is applied to the tip, and the collector is maintained at a distance of 100–200 mm. Ambient relative humidity must be controlled below 30% RH; above 50% RH water uptake destabilizes the Taylor cone and produces bead-on-string defects on the drum. A rotating mandrel at 300–500 rpm collects fibers with diameters typically between 500 nm and 2000 nm, measured by scanning electron microscopy. The resulting pore size and through-thickness transport can be shifted by changing fiber diameter, drum rotation speed, and deposition time. After spinning, the scaffold is vacuum-dried at 40 °C for 48 h to reduce residual chloroform toward the limits enforced by USP 467 and ICH Q3C(R8). For tissue engineering applications such as nerve guidance conduits, vascular scaffolds, and tendon augmentation patches, ISO 10993-5 and ISO 10993-6 are the primary acute safety anchors; ISO 10993-12 must define the extraction procedure because chloroform-cast PLGA can retain low-molecular-weight leachables that are cytotoxic in high surface-area formats. Tensile evaluation of nonwoven electrospun materials by ASTM D638-14 is often inadequate because bulk film assumptions do not apply; suture retention strength and burst pressure are more relevant. Published peer-reviewed data on long-term degradation mechanics of 85:15 PLGA electrospun tubes in human musculoskeletal or vascular sites is limited, so implantation studies under ISO 10993-6 are required before safety endpoints are claimed.

N-Methyl-2-Pyrrolidone Phase Inversion Produces a Burst Release Threshold in Subcutaneous Depots

With N-methyl-2-pyrrolidone as the solvent, 85:15 DL-PLG is dissolved at 30–50% w/w; addition of polyethylene glycol 300 at 5–10% w/w lowers solution viscosity and modifies the porosity of the precipitated depot. The formulation is injected through a 21 G needle, and syringeability requires viscosity below 1000 mPa·s at 25 °C. Contact with subcutaneous or intramuscular water causes solvent exchange and polymer precipitation; because NMP is highly water-miscible, rapid water ingress can produce a dense outer skin and aqueous channels, increasing the initial 24 h release. Burst release is assessed by rotating vial or flow-through methods, and the acceptability threshold depends on the active pharmaceutical ingredient therapeutic window; published data for this specific PLGA grade and solvent combination is limited, so formulation-specific in vitro and in vivo correlation is required. Residual NMP in the finished injectable is controlled to 530 µg/g under ICH Q3C(R8), and moisture in the organic solution is limited by preparing and storing it at 2–8 °C under nitrogen. The terminal product is a prefilled syringe or vial containing a sterile non-aqueous solution; moist heat sterilization is incompatible with hydrolysis, gamma irradiation degrades the copolymer, and ethylene oxide absorption is difficult in anhydrous solutions, so filtration or aseptic processing is preferred. If sterile filtration is used, membrane compatibility and viscosity must be validated; if aseptic processing is used, bioburden control and media fill requirements under ISO 13485 and current good manufacturing practice apply. Biological evaluation is anchored to ISO 10993-5 for cytotoxicity, ISO 10993-6 for local tissue response, and ISO 10993-10 for irritation and sensitization. The high-lactide ratio delays bulk degradation relative to lower-lactide PLGA, but the depot’s functional lifetime cannot be inferred from polymer composition alone and must be verified by mass loss and molecular weight measurements in vivo.

Guided bone regeneration membranes from 85:15 DL-PLG are produced by solvent casting and salt leaching rather than melt pressing because the polymer is amorphous and has low melt strength. The copolymer is dissolved in dichloromethane at 10–15% w/w, and sodium chloride particles sieved to 100–300 µm are dispersed at 70–85% w/w of the polymer-salt blend. The mixture is cast onto a polyethylene release liner with a blade gap that determines the final membrane thickness of 200–500 µm. Leaching is performed in water-for-injection changed at 8 h intervals for 48–72 h to avoid osmotically retained salt pockets; incomplete leaching leaves radiopaque salt domains and increases local hypertonicity. Porosity is verified by mercury intrusion porosimetry or scanning electron microscopy, and residual solvent is controlled under ICH Q3C(R8). The terminal product is a sterile resorbable barrier membrane for dental bone regeneration; because the 85:15 copolymer degrades more slowly than 50:50 PLGA, barrier function tends to persist longer, but final mass loss is site-specific. In oral use the pH can fluctuate between 6.5 and 7.4, and esterase activity accelerates hydrolytic degradation relative to pH-buffered saline, so in vitro mass loss alone does not establish functional barrier duration. Suture retention strength is a limiting mechanical property, and fixation by tacks or screws is used when primary closure is not sufficient. Biological evaluation is anchored to ISO 10993-6 for implantation, ISO 10993-10 for sensitization, ISO 10993-11 for systemic toxicity, and ISO 10993-12 for extractables under high-surface-area conditions.